Page last updated: 2024-10-27

fluorouracil and Symptom Cluster

fluorouracil has been researched along with Symptom Cluster in 96 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib."9.19Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014)
"Capecitabine is an established therapy for metastatic breast cancer."9.14Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010)
"To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine."9.14Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010)
"For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used."9.14A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009)
"Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated."9.14Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010)
"This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer."9.11A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."9.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen."9.07A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991)
" The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer."8.83Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006)
"Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine."8.82Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004)
"Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)."8.82Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004)
"Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)."8.82Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004)
"Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil."8.82Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004)
"Cholinergic syndrome is an acute adverse reaction associated with irinotecan."7.88Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."7.77A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin."7.76High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010)
"Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas."7.76Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010)
" The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy."7.75Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."7.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine."7.74[Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007)
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy."7.74[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008)
"A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation."7.73Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006)
"Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy."7.72Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."7.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."7.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53."7.685-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991)
"A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented."7.67Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988)
"Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials."6.71Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003)
"Capecitabine is a chemotherapeutic drug for use in cancers."5.35Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008)
"Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms."5.34Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007)
"This patient with DPD deficiency manifested a variant of HFS."5.33Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006)
"Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death."5.31A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002)
"Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib."5.19Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014)
"For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used."5.14A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009)
"Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated."5.14Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010)
"To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer."5.14[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010)
"To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine."5.14Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010)
"Capecitabine is an established therapy for metastatic breast cancer."5.14Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010)
"Effects of a single administration of small doses of 5-fluorouracil on results of skin plasty for syndrome of the diabetic foot were studied in 61 patients who had undergone local operations for pyo-necrotic diseases of the foot against the background of diabetes mellitus."5.12[Effects of short-term immunosuppression on the engraftment of skin transplants at syndrome of the diabetic foot]. ( Belov, VV; Bordunovskiĭ, VN; Grekova, NM; Lebedeva, IuV; Tertyshnik, SS, 2007)
"This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer."5.11A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."5.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen."5.07A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991)
"Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil."4.87[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. ( Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011)
" The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer."4.83Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006)
"Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil."4.82Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004)
"Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine."4.82Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004)
"Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)."4.82Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004)
"Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)."4.82Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004)
" Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted."3.91[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome]. ( Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K, 2019)
"Cholinergic syndrome is an acute adverse reaction associated with irinotecan."3.88Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018)
"The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60) chemotherapy."3.79Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."3.77A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin."3.76High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010)
"Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas."3.76Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010)
" The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy."3.75Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009)
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy."3.74[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."3.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine."3.74[Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007)
"A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation."3.73Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006)
"Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy."3.72Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."3.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma."3.70Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."3.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53."3.685-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991)
"The watery diarrhea-hypokalemia-achlorhydria syndrome associated with ectopic secretion of vasoactive intestinal peptide has only been conclusively documented with tumors originating in the pancreas or sympathetic chain."3.67Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. ( Douglas, MC; Hurley, R; Kalnins, R; Moran, L; Shulkes, A; Smallwood, RA; Watson, KJ, 1985)
"A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented."3.67Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988)
"Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU."3.66Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983)
"Hyperpigmentation is a rare side effect occurring with 5-FU infusions; it has been reported in 2-5% of patients."2.82Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review. ( Basu, D; Chaudhary, K; Goel, V; Jain, A; Narayan, S; Redhu, P; Soni, S; Talwar, V, 2022)
"Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials."2.71Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003)
" HFS is a leading cause of treatment interruption, dosage reduction, or, even, therapy discontinuation for patients on a capecitabine regimen."2.44Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? ( Goldberg, RM; McLeod, HL; Yen-Revollo, JL, 2008)
"Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy."2.44Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007)
"Capecitabine is a chemotherapeutic drug for use in cancers."1.35Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008)
"Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms."1.34Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007)
"This patient with DPD deficiency manifested a variant of HFS."1.33Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006)
"Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death."1.31A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002)
"Leser-Trélat-syndrome is characterized as the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease."1.31[Clinical and histopathological characteristics of early Leser-Trélat syndrome]. ( Barth, G; Basten, O; Rompel, R; Rüschoff, J, 2001)
"The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications."1.27Renal complications of cytotoxic therapy. ( Clarkson, AR; Healy, HG, 1983)

Research

Studies (96)

TimeframeStudies, this research(%)All Research%
pre-199024 (25.00)18.7374
1990's10 (10.42)18.2507
2000's45 (46.88)29.6817
2010's16 (16.67)24.3611
2020's1 (1.04)2.80

Authors

AuthorsStudies
Narayan, S3
Talwar, V3
Redhu, P3
Goel, V3
Jain, A3
Soni, S3
Chaudhary, K3
Basu, D3
Kanbayashi, Y1
Ishikawa, T2
Kanazawa, M1
Nakajima, Y1
Tabuchi, Y1
Kawano, R1
Yoshioka, T1
Yoshida, N1
Hosokawa, T1
Takayama, K1
Taguchi, T2
Tashima, Y1
Kusanagi, K1
Takeda, Y1
Yoshimatsu, K1
Ishida, T1
Shinohara, S1
Hirai, A1
Imanishi, N1
Ichiki, Y1
Tanaka, F1
Riezzo, G1
Clemente, C1
Linsalata, M1
D'Attoma, B1
Orlando, A1
Campanella, G1
Giotta, F1
Russo, F1
Goto, N1
Mimura, J1
Saura, C1
Garcia-Saenz, JA2
Xu, B1
Harb, W1
Moroose, R1
Pluard, T1
Cortés, J1
Kiger, C1
Germa, C1
Wang, K1
Martin, M2
Baselga, J1
Kim, SB2
Matsuda, S1
Koketsu, H1
Hayakawa, M1
Nagata, N1
Browall, M1
Brandberg, Y1
Nasic, S1
Rydberg, P1
Bergh, J1
Rydén, A1
Xie, H1
Eriksson, I1
Wengström, Y1
Fujii, C1
Anami, S1
Fujino, M2
Yasui, Y1
Fujita, M1
Inoue, M1
Nakayama, T2
Kamigaki, S1
Tatsuta, M1
Furukawa, H1
Perboni, S1
Bowers, C1
Kojima, S1
Asakawa, A1
Inui, A1
Hénin, E1
You, B1
VanCutsem, E1
Hoff, PM2
Cassidy, J1
Twelves, C1
Zuideveld, KP1
Sirzen, F1
Dartois, C1
Freyer, G1
Tod, M1
Girard, P1
Matsuyama, T1
Uetake, H1
Aoyagi, H1
Kobayashi, H1
Iida, S1
Higuchi, T1
Yasuno, M1
Enomoto, M1
Sugihara, K1
Lee, YJ1
Lee, HJ2
Jeong, KC1
Kang, JG1
Lee, SH1
Kim, YT1
Son, HS1
Lee, WY1
Lee, WS1
Yun, SH1
Chun, HK1
Latif, S1
Fraga, G1
Gadzia, J1
Lu, GC1
Fang, F1
Li, DC1
Masuda, N1
Yoshidome, K1
Akagi, K1
Nishida, Y1
Yoshikawa, Y1
Ogino, N1
Abe, C1
Sakamoto, J2
Noguchi, S1
Kang, YK2
Lee, SS1
Yoon, DH1
Lee, SY1
Chun, YJ1
Kim, MS1
Ryu, MH2
Chang, HM2
Lee, JL1
Kim, TW2
Kamil, M1
Haron, M1
Yosuff, N1
Khalid, I1
Azman, N1
Jeung, HC1
Chung, HC1
Wolf, SL1
Qin, R1
Menon, SP1
Rowland, KM1
Thomas, S1
Delaune, R1
Christian, D1
Pajon, ER1
Satele, DV1
Berenberg, JL1
Loprinzi, CL1
Caronia, D1
Sastre, J1
de la Torre, J1
Alonso, MR1
Moreno, LT1
Pita, G1
Díaz-Rubio, E1
Benítez, J1
González-Neira, A1
Bartal, A1
Mátrai, Z1
Szûcs, A1
Liszkay, G1
Gorgulu, S1
Celik, S1
Tezel, T1
Scheithauer, W2
Schüll, B1
Ulrich-Pur, H1
Schmid, K1
Raderer, M1
Haider, K1
Kwasny, W1
Depisch, D1
Schneeweiss, B1
Lang, F1
Kornek, GV1
Lin, E1
Morris, JS1
Ayers, GD1
Risum, S1
Langer, SW1
Childress, J1
Lokich, J1
Park, YH1
Ryoo, BY1
Kim, SA1
Chung, JH1
Takahashi, K1
Mori, T1
Yamaguchi, T1
Matsumoto, H1
Miyamoto, H1
Arai, K1
Iwasaki, Y1
Katayanagi, S1
Narasimhan, P1
Narasimhan, S1
Hitti, IF1
Rachita, M1
Kondo, Y1
Takemiya, S1
Sakamoto, N1
Nishisho, I1
Lassere, Y1
Hoff, P1
Heo, YS1
Ahn, JH1
Lee, JS1
Kim, WK1
Cho, HK1
Ezzeldin, H1
Diasio, R2
Blum, J1
Fischel, JL1
Formento, P1
Ciccolini, J1
Etienne-Grimaldi, MC1
Milano, G1
Komatsu, Y1
Takei, M1
Yuki, S1
Fuse, N1
Furukawa, S1
Kato, T1
Takeda, H1
Kato, M1
Asaka, M1
Cardinale, D1
Colombo, A1
Colombo, N1
Gugerli, O1
Leupin, N1
Kurt, M1
Aksoy, S1
Guler, N1
Marini, A1
Hengge, UR1
Gundling, F1
Fuchs, M1
Nowak, L1
Antoni, D1
Hoffmann, E1
Schepp, W1
Gressett, SM1
Stanford, BL1
Hardwicke, F1
Saif, MW1
Elfiky, A1
Guedin, P1
Chasle, J1
Blanc-Fournier, C1
Lacroix, J1
Wang, Y1
Xu, RR1
Webster-Gandy, JD1
How, C1
Harrold, K1
Do, JE1
Kim, YC1
Shimomatsuya, T1
Mitsudou, Y1
Nakamura, T1
Yonezawa, K1
Shiraishi, S1
Maruhashi, K1
Ota, K1
Kishida, S1
Yucel, I1
Guzin, G1
Belov, VV1
Bordunovskiĭ, VN1
Grekova, NM1
Lebedeva, IuV1
Tertyshnik, SS1
Yen-Revollo, JL1
Goldberg, RM1
McLeod, HL1
Trindade, F1
Haro, R1
Fariña, MC1
Requena, L1
Lempert, KD1
Healy, HG1
Clarkson, AR1
Jolivet, J1
Giroux, L1
Laurin, S1
Gruber, J1
Bettez, P1
Band, PR1
Maisin, H2
Anckaert, MA2
De Coster, BM2
Lokich, JJ1
Moore, C1
Hagstrom, WJ1
Faibisoff, B1
Soltani, K1
Robson, MC1
McDonald, SG1
Peterka, ES1
Benoldi, D1
Pezzarossa, E1
Alinovi, A1
Labrini, G1
Marcheselli, W1
de Panfilis, G1
Manfredi, G1
Weidmann, B1
Teipel, A1
Niederle, N1
Robben, NC1
Pippas, AW1
Moore, JO1
Burnet, NG1
Mason, MD1
Hanson, JA1
Wurm, R1
Peacock, JH1
Chiara, S1
Nobile, MT1
Barzacchi, C1
Sanguineti, O1
Vincenti, M1
Di Somma, C1
Meszaros, P1
Rosso, R1
Iurlo, A1
Fornier, M1
Caldiera, S1
Bertoni, F1
Foa, P1
Noguerón, E1
Berrocal, A1
Albert, A1
Camps, C1
Vicent, JM1
Bak, A1
Lim, WT1
Koo, WH1
Au, E1
Khoo, KS1
Yan, H1
Pestieau, SR1
Shmookler, BM1
Sugarbaker, PH2
Barth, G1
Basten, O1
Rüschoff, J1
Rompel, R1
Rothenberg, ML1
Meropol, NJ1
Poplin, EA1
Van Cutsem, E1
Wadler, S1
Doe, EA1
Budenz, DL1
Gedde, SJ1
Imami, NR1
Bleiberg, H1
Di Leo, A1
Abushullaih, S1
Saad, ED1
Munsell, M1
Stone, SP1
Labandter, HP2
Ryan, RF2
Goette, DK1
Gartmann, H1
Habal, MB1
Biano, G1
Cavins, JA1
Boileau, GA1
Klein, E1
Murray, JE1
Kemeny, N1
Seiter, K1
Martin, D1
Urmacher, C1
Niedzwiecki, D1
Kurtz, RC1
Costa, P1
Murray, M1
Wright, MM1
Grajewski, AL1
Cristol, SM1
Parrish, RK1
Vukelja, SJ1
Lombardo, FA1
James, WD1
Weiss, RB1
Altimari, AF1
Bhoopalam, N1
O'Dorsio, T1
Lange, CL1
Sandberg, L1
Prinz, RA1
Watson, KJ1
Shulkes, A1
Smallwood, RA1
Douglas, MC1
Hurley, R1
Kalnins, R1
Moran, L1
Sillman, FH1
Sedlis, A1
Boyce, JG1
Bellmunt, J1
Navarro, M1
Hidalgo, R1
Solé, LA1
Niehoff, M1
Redman, JF1
Turley, JT1
Weiss, HD1
Walker, MD1
Wiernik, PH1
Moynahan, EJ1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260]Phase 1/Phase 2105 participants (Actual)Interventional2008-12-09Completed
Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome[NCT00446147]Phase 3389 participants (Actual)Interventional2004-06-30Completed
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552]Phase 3870 participants (Anticipated)Interventional2013-08-19Recruiting
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726]90 participants (Anticipated)Interventional2023-05-16Recruiting
A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036]Phase 3137 participants (Actual)Interventional2006-06-30Completed
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]Phase 266 participants (Anticipated)Interventional2022-12-08Active, not recruiting
The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034]14 participants (Actual)Interventional2020-08-04Terminated (stopped due to Principal Investigator retired before study completed.)
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028]Phase 2100 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Benefit Rate

The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.

Interventionpercentage of participants (Number)
Prior Lapatinib Subjects71.4
Lapatinib Naive Subjects P172.1
Lapatinib Naive Subjects Part 2 + Part 173.0

Duration of Response

Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.

Interventionweeks (Median)
Prior Lapatinib Subjects48.3
Lapatinib Naive Subjects P146.3
Lapatinib Naive Subjects Part 2 + Part 146.3

Maximum Tolerated Dose (MTD) of Capecitabine

MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.

Interventionmg/m^2 (Number)
Capecitabine in Combination With Neratinib1500

Maximum Tolerated Dose (MTD) of Neratinib

MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.

Interventionmg (Number)
Neratinib in Combination With Capecitabine240

Number of Participants With Dose Limiting Toxicities

Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21

InterventionParticipants (Count of Participants)
N160 + C15000
N160 + C20002
N200 + C20002
N240 + C15000
N240 + C20002
N + C MTD - No Prior Lap0
N + C MTD - Prior Lap0

Overall Response Rate

Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.

Interventionpercentage of participants (Number)
Prior Lapatinib Subjects57.1
Lapatinib Naive Subjects P163.9
Lapatinib Naive Subjects Part 2 + Part 163.5

Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome

A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy. (NCT00446147)
Timeframe: Up to 2 years

Interventionmiligram per square meter (Median)
Placebo70000
Pyridoxine70000

Number of Patients With Hand-foot Syndrome

Number of patients with any grade of hand-foot syndrome (NCT00446147)
Timeframe: Up to 2 years

Interventionparticipants (Number)
Placebo55
Pyridoxine57

To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia

A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment

Interventionpercentage of participants (Number)
Urea/Lactic Acid Cream13.6
Placebo Cream10.2

To Evaluate the Potential Toxicity of Urea/Lactic Acid Cream

Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles

,
Interventionparticipants (Number)
Grade 3+ Adverse EventGrade 4+ Adverse Event
Placebo Cream183
Urea/Lactic Acid Cream213

Reviews

15 reviews available for fluorouracil and Symptom Cluster

ArticleYear
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
    The Gulf journal of oncology, 2022, Volume: 1, Issue:40

    Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome

2022
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
    The Gulf journal of oncology, 2022, Volume: 1, Issue:40

    Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome

2022
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
    The Gulf journal of oncology, 2022, Volume: 1, Issue:40

    Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome

2022
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
    The Gulf journal of oncology, 2022, Volume: 1, Issue:40

    Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome

2022
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
    Magyar onkologia, 2011, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil

2011
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
    Cutis, 2004, Volume: 73, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Black People; Capecitabine; Deoxycytidine; Erythema; F

2004
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab

2004
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
    Clinical colorectal cancer, 2004, Volume: 4, Issue:3

    Topics: Antimetabolites, Antineoplastic; Diagnosis, Differential; Dihydropyrimidine Dehydrogenase Deficiency

2004
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:9

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine

2004
Management of hand-foot syndrome induced by capecitabine.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2006, Volume: 12, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Foot Injuries; Hand Inju

2006
[Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Therapy; Drugs, Chinese Herbal; F

2007
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2007, Volume: 11, Issue:3

    Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine;

2007
[Drug-induced leukoencephalopathy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Aug-10, Volume: 96, Issue:8

    Topics: Antineoplastic Agents; Brain Edema; Cisplatin; Cytarabine; Fluorouracil; Humans; Hypertensive Enceph

2007
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-01, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorouracil; Foot Der

2008
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.
    Cancer, 1993, Jan-15, Volume: 71, Issue:2

    Topics: Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Pyrimidines; Syndrome

1993
Review of erythroplasia of Queyrat and its treatment.
    Urology, 1976, Volume: 8, Issue:4

    Topics: Adult; Aged; Erythroplasia; Fluorouracil; Humans; Male; Middle Aged; Penile Neoplasms; Precancerous

1976
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil.
    Obstetrical & gynecological survey, 1985, Volume: 40, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc

1985
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
    The New England journal of medicine, 1974, 07-11, Volume: 291, Issue:2

    Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia;

1974

Trials

12 trials available for fluorouracil and Symptom Cluster

ArticleYear
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32

    Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot

2014
A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cluster Analysis; Cyc

2017
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura

2009
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2010
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Chemotherapy, 2010, Volume: 56, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant

2010
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou

2010
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou

2010
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou

2010
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou

2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind

2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind

2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind

2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind

2010
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols

2003
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
    Anti-cancer drugs, 2004, Volume: 15, Issue:2

    Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre

2004
[Effects of short-term immunosuppression on the engraftment of skin transplants at syndrome of the diabetic foot].
    Vestnik khirurgii imeni I. I. Grekova, 2007, Volume: 166, Issue:5

    Topics: Biopsy; Blood Transfusion, Autologous; Diabetic Foot; Female; Fluorouracil; Follow-Up Studies; Graft

2007
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
    Cancer investigation, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil

2002
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
    Annals of internal medicine, 1991, Dec-15, Volume: 115, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms;

1991

Other Studies

69 other studies available for fluorouracil and Symptom Cluster

ArticleYear
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
    Medical oncology (Northwood, London, England), 2018, Apr-28, Volume: 35, Issue:6

    Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo

2018
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
    Journal of UOEH, 2019, Volume: 41, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined M

2019
Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth

2013
Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Unilateral Capecitabine-related Hand-foot Syndrome.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:21

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon

2015
[Management of hand-foot syndrome in patient treated with capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil

2008
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
    World journal of gastroenterology, 2008, Nov-07, Volume: 14, Issue:41

    Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell

2008
[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Fluorouracil; Foot; Hand; Humans; Male; Middle Age

2008
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul

2009
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Yonsei medical journal, 2009, Dec-31, Volume: 50, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasm

2009
Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Count; Deoxycytidine; Female; Fluorouracil

2010
High frequency of hand foot syndrome with capecitabine.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St

2010
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fl

2010
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas

2011
A case of coronary spasm induced by 5-fluorouracil.
    Acta cardiologica, 2002, Volume: 57, Issue:5

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Chest Pain; Colonic Neoplasms; Coronary Angiography;

2002
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms;

2002
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Ugeskrift for laeger, 2003, Aug-11, Volume: 165, Issue:33

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R

2003
Cutaneous hand and foot toxicity associated with cancer chemotherapy.
    American journal of clinical oncology, 2003, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Eruptions; Erythema; Fluorouracil; Foot; Hand; H

2003
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluo

2003
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration

2003
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
    Journal of clinical pharmacology, 2004, Volume: 44, Issue:10

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cli

2004
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
    Anti-cancer drugs, 2004, Volume: 15, Issue:10

    Topics: Antineoplastic Agents; beta-Alanine; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Resp

2004
Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gilbert Disease; G

2005
Acute coronary syndrome induced by oral capecitabine.
    The Canadian journal of cardiology, 2006, Mar-01, Volume: 22, Issue:3

    Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone

2006
[Blisters unlike others].
    Revue medicale suisse, 2006, Apr-19, Volume: 2, Issue:62

    Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female;

2006
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca

2006
[Hand-foot syndrome with capecitabine therapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2007, Volume: 58, Issue:6

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neopl

2007
["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
    Zeitschrift fur Gastroenterologie, 2006, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Angina Pectoris; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Fluoro

2006
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt

2006
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
    Journal de radiologie, 2006, Volume: 87, Issue:11 Pt 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breas

2006
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:5

    Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; F

2007
[A case of severe hand-foot syndrome caused by capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration

2007
Topical henna for capecitabine induced hand-foot syndrome.
    Investigational new drugs, 2008, Volume: 26, Issue:2

    Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine

2008
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
    The American Journal of dermatopathology, 2008, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel

2008
Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.
    Lancet (London, England), 1980, Aug-16, Volume: 2, Issue:8190

    Topics: Aged; Anemia, Hemolytic; Fluorouracil; Humans; Kidney; Kidney Diseases; Male; Mitomycins; Stomach Ne

1980
Renal complications of cytotoxic therapy.
    Australian and New Zealand journal of medicine, 1983, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Cytarabine; Dogs; Fluorou

1983
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
    Cancer treatment reports, 1983, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K

1983
[Combination chemotherapy and radiotherapy. Differential effect, on the intestinal syndrome, of fractionated irradiation with fractionated drug administration].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1982, Volume: 176, Issue:1

    Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; Intestinal Dise

1982
[Combination chemotherapy and radiotherapy. Differential effect, on the medullary syndrome, of fractionated irradiation with fractionated drug administration].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1982, Volume: 176, Issue:1

    Topics: Animals; Brain Diseases; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil;

1982
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
    Annals of internal medicine, 1984, Volume: 101, Issue:6

    Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule;

1984
Dysplastic nevus syndrome (B-K mole syndrome).
    Plastic and reconstructive surgery, 1983, Volume: 71, Issue:2

    Topics: Dermabrasion; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Nevus, Pigmented

1983
Porokeratosis (Mibelli): treatment with topical 5-fluorouracil.
    Journal of the American Academy of Dermatology, 1983, Volume: 8, Issue:1

    Topics: Administration, Topical; Adult; Fluorouracil; Hand Dermatoses; Humans; Keratosis; Male; Skin; Syndro

1983
[Retinoic acid and 5-FU mixture in the topical treatment of several skin diseases (author's transl)].
    L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma, 1980, Volume: 51, Issue:3

    Topics: Drug Combinations; Fluorouracil; Humans; Keratosis; Ointments; Radiation Injuries; Skin Diseases; Sy

1980
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
    Cancer, 1994, Apr-01, Volume: 73, Issue:7

    Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H

1994
Thrombocytopenia with absent radii (TAR) syndrome: a new increased cellular radiosensitivity syndrome.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1995, Volume: 7, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cell Survival; Chromatids; Fibroblasts; Fluorouracil; G2 Phase; Hum

1995
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:6

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1997
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Erythema; Female; F

1997
[Acute cerebellar syndrome due to 5-fluorouracil].
    Revista de neurologia, 1997, Volume: 25, Issue:148

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Headache; Humans; M

1997
[A case of Cogan-Reese syndrome (iris nevus syndrome)].
    Klinika oczna, 1997, Volume: 99, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; F

1997
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
    Annals of the Academy of Medicine, Singapore, 1999, Volume: 28, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic

1999
Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2001, Volume: 14, Issue:3

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic;

2001
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2001, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive Syste

2001
[Clinical and histopathological characteristics of early Leser-Trélat syndrome].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2001, Volume: 52, Issue:7

    Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colon; Colonic Neoplasms; Colonosco

2001
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Sep-15, Volume: 19, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastroin

2001
Long-term surgical outcomes of patients with glaucoma secondary to the iridocorneal endothelial syndrome.
    Ophthalmology, 2001, Volume: 108, Issue:10

    Topics: Adult; Antihypertensive Agents; Corneal Diseases; Endothelium, Corneal; Fluorouracil; Follow-Up Stud

2001
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-15, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Ne

2002
Basal cell nevus syndrome and adenocarcinoma of the colon. Response to systemic fluorouracil.
    International journal of dermatology, 1979, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Carcinoma, Basal Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Nevus

1979
5-fluorouracil in management of Gorlin's syndrome.
    The New England journal of medicine, 1978, Apr-20, Volume: 298, Issue:16

    Topics: Aged; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Skin Neoplasms; Syndrome

1978
5-fluorouracil in Gorlin's syndrome.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1978, Volume: 130, Issue:4

    Topics: Aged; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Jaw Diseases; Skin Neoplasms; Syndrome

1978
[Topical use of antineoplastic agents in precancerous conditions of the skin].
    Zeitschrift fur Hautkrankheiten, 1977, Apr-15, Volume: 52, Issue:8

    Topics: Administration, Topical; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Kera

1977
The "turban" nevoid basal cell syndrome. Current management with surgery, chemotherapy and immunotherapy.
    International surgery, 1975, Volume: 60, Issue:9

    Topics: Adult; Bone Cysts; Carcinoma, Basal Cell; Dinitrochlorobenzene; Fluorouracil; Humans; Jaw Diseases;

1975
5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome.
    Ophthalmology, 1991, Volume: 98, Issue:3

    Topics: Adult; Cataract Extraction; Conjunctiva; Corneal Diseases; Endothelium, Corneal; Fluorouracil; Follo

1991
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
    Annals of internal medicine, 1989, Oct-15, Volume: 111, Issue:8

    Topics: Dermatitis, Exfoliative; Fluorouracil; Hand Dermatoses; Humans; Male; Middle Aged; Nervous System Di

1989
Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
    Surgery, 1986, Volume: 100, Issue:6

    Topics: Adenoma, Islet Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz

1986
Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus.
    Gastroenterology, 1985, Volume: 88, Issue:3

    Topics: Achlorhydria; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid;

1985
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
    Tumori, 1988, Jun-30, Volume: 74, Issue:3

    Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia

1988
[Case demonstration: Papillomatosis cutis carcinoides (Gottron) in epidermolysis bullosa dystrophica].
    Zeitschrift fur Hautkrankheiten, 1974, Jul-01, Volume: 49, Issue:13

    Topics: Adult; Bleomycin; Epidermolysis Bullosa; Female; Fluorouracil; Foot; Hand; Humans; Leg; Lymphadeniti

1974
Failure of chemotherapy in treatment of giant condyloma acuminata (Buschke-Loewenstein tumor).
    Southern medical journal, 1974, Volume: 67, Issue:6

    Topics: Adult; Condylomata Acuminata; Fluorouracil; Humans; Male; Penile Diseases; Penis; Plant Extracts; Pl

1974
Multiple basal cell naevus syndrome--successful treatment of basal cell tumours with 5-fluorouracil.
    Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:7

    Topics: Adult; Carcinoma, Basal Cell; Dentigerous Cyst; Fluorouracil; Humans; Jaw Diseases; Male; Skin Neopl

1973